← The SEC Ephemeris: the whole map
Astellas Pharma US, Inc. IZERVAY
In the graph: all 3 documents (8 pages).
- Application
- NDA 217225
- Ticker
- Astellas Pharma US, Inc.
- Product
- IZERVAY
- Disease area
- Not yet classified
- Response path
- Not yet classified
- Complete Response Letters
- November 15, 2024 · January 4, 2024 · August 28, 2017
From FDA letters and SEC filings. Not investment or medical advice.